Regulatory and evidence-based considerations for abuse-deterrent opioids

被引:2
|
作者
Loeser, Kathryn C. [1 ]
Rodriguez, Ryan [2 ]
机构
[1] Takeda Pharmaceut USA Inc, Deerfield, IL 60015 USA
[2] Univ Illinois, Coll Pharm, Chicago, IL USA
关键词
EXTENDED-RELEASE OXYCODONE; ROUTES;
D O I
10.1093/ajhp/zxy013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:114 / 118
页数:5
相关论文
共 50 条
  • [1] Abuse-Deterrent Opioids
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2017, 59 (1522): : 95 - 96
  • [2] Abuse-deterrent opioids: an update on current approaches and considerations
    Pergolizzi, Joseph V., Jr.
    Raffa, Robert B.
    Taylor, Robert, Jr.
    Vacalis, Steven
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (04) : 711 - 723
  • [3] Abuse-Deterrent Opioids: The Authors Reply
    Powell, David
    Alpert, Abby
    Pacula, Rosalie L.
    [J]. HEALTH AFFAIRS, 2019, 38 (04)
  • [4] Abuse-Deterrent Formulations of Prescription Opioids
    Ruan, Xiulu
    Chiravuri, Srinivas
    Kaye, Alan D.
    [J]. JAMA PSYCHIATRY, 2015, 72 (08) : 849 - 850
  • [5] Statistical assessment of abuse-deterrent opioids
    Chen, Ling
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2017, 171 : E40 - E40
  • [6] Final Guidance Issued on Abuse-Deterrent Opioids
    Rubin, Rita
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (17): : 1704 - 1704
  • [7] Key Facts about “Abuse-Deterrent” Opioids
    Douglas C.Throckmorton
    [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25 (11) : 855 - 856
  • [8] Benefits, Limitations, and Value of Abuse-Deterrent Opioids
    Curfman, Gregory D.
    Beletsky, Leo
    Sarpatwari, Ameet
    [J]. JAMA INTERNAL MEDICINE, 2018, 178 (01) : 131 - 132
  • [9] Abuse-Deterrent Formulations of Prescription Opioids Reply
    Cicero, Theodore J.
    Ellis, Matthew S.
    [J]. JAMA PSYCHIATRY, 2015, 72 (08) : 850 - 851
  • [10] Abuse-deterrent opioids: Worth the cost and effort?
    Nguyen, Tien M.
    [J]. CHEMICAL & ENGINEERING NEWS, 2017, 95 (45) : 34 - 36